Do children and adolescents with ADHD respond differently to atomoxetine?

Timothy E. Wilens, Christopher J Kratochvil, Jeffrey H. Newcorn, Haitao Gao

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: Controversy exists over changes in tolerability and response to medications across the life span. Here the authors report data contrasting the efficacy and tolerability of atomoxetine between children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Method: Data were analyzed for children ages 6-11 (510 atomoxetine, 341 placebo) and adolescents ages 12-17 (107 atomoxetine, 69 placebo) with DSM-IV-defined ADHD enrolled in similarly designed, double-blind, placebo-controlled trials. Efficacy measures included response rates, times to response, and mean changes from baseline to endpoint in the ADHD Rating Scale, Conners' Parent Rating Scale, and Clinical Global Impressions. Results: Adolescents had lower baseline ADHD scores compared with children. There were no statistically significant differences in the overall effects on ADHD symptoms, response rates, or time to response between age groups. Children, but not adolescents, had higher rates of somnolence and headache relative to placebo. No other clinically meaningful treatment differences were seen in adverse event rates, vital signs, weight, height, laboratory values, or ECG between children and adolescents. Conclusions: Acute atomoxetine treatment appears to be equally effective and tolerated in children and adolescents. These findings suggest that pharmacological differences in tolerability or ADHD symptom response are negligible between children and adolescents.

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number2
DOIs
StatePublished - Jan 1 2006

Fingerprint

Attention Deficit Disorder with Hyperactivity
Placebos
Vital Signs
Atomoxetine Hydrochloride
Diagnostic and Statistical Manual of Mental Disorders
Headache
Electrocardiography
Age Groups
Pharmacology
Weights and Measures
Therapeutics

Keywords

  • Adolescents
  • Age
  • Atomoxetine
  • Attention-deficit/hyperactivity disorder
  • Children

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Do children and adolescents with ADHD respond differently to atomoxetine? / Wilens, Timothy E.; Kratochvil, Christopher J; Newcorn, Jeffrey H.; Gao, Haitao.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 2, 01.01.2006, p. 149-157.

Research output: Contribution to journalArticle

@article{e27db32185f24d4993d062143f44daac,
title = "Do children and adolescents with ADHD respond differently to atomoxetine?",
abstract = "Objective: Controversy exists over changes in tolerability and response to medications across the life span. Here the authors report data contrasting the efficacy and tolerability of atomoxetine between children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Method: Data were analyzed for children ages 6-11 (510 atomoxetine, 341 placebo) and adolescents ages 12-17 (107 atomoxetine, 69 placebo) with DSM-IV-defined ADHD enrolled in similarly designed, double-blind, placebo-controlled trials. Efficacy measures included response rates, times to response, and mean changes from baseline to endpoint in the ADHD Rating Scale, Conners' Parent Rating Scale, and Clinical Global Impressions. Results: Adolescents had lower baseline ADHD scores compared with children. There were no statistically significant differences in the overall effects on ADHD symptoms, response rates, or time to response between age groups. Children, but not adolescents, had higher rates of somnolence and headache relative to placebo. No other clinically meaningful treatment differences were seen in adverse event rates, vital signs, weight, height, laboratory values, or ECG between children and adolescents. Conclusions: Acute atomoxetine treatment appears to be equally effective and tolerated in children and adolescents. These findings suggest that pharmacological differences in tolerability or ADHD symptom response are negligible between children and adolescents.",
keywords = "Adolescents, Age, Atomoxetine, Attention-deficit/hyperactivity disorder, Children",
author = "Wilens, {Timothy E.} and Kratochvil, {Christopher J} and Newcorn, {Jeffrey H.} and Haitao Gao",
year = "2006",
month = "1",
day = "1",
doi = "10.1097/01.chi.0000190352.90946.0b",
language = "English (US)",
volume = "45",
pages = "149--157",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Do children and adolescents with ADHD respond differently to atomoxetine?

AU - Wilens, Timothy E.

AU - Kratochvil, Christopher J

AU - Newcorn, Jeffrey H.

AU - Gao, Haitao

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Objective: Controversy exists over changes in tolerability and response to medications across the life span. Here the authors report data contrasting the efficacy and tolerability of atomoxetine between children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Method: Data were analyzed for children ages 6-11 (510 atomoxetine, 341 placebo) and adolescents ages 12-17 (107 atomoxetine, 69 placebo) with DSM-IV-defined ADHD enrolled in similarly designed, double-blind, placebo-controlled trials. Efficacy measures included response rates, times to response, and mean changes from baseline to endpoint in the ADHD Rating Scale, Conners' Parent Rating Scale, and Clinical Global Impressions. Results: Adolescents had lower baseline ADHD scores compared with children. There were no statistically significant differences in the overall effects on ADHD symptoms, response rates, or time to response between age groups. Children, but not adolescents, had higher rates of somnolence and headache relative to placebo. No other clinically meaningful treatment differences were seen in adverse event rates, vital signs, weight, height, laboratory values, or ECG between children and adolescents. Conclusions: Acute atomoxetine treatment appears to be equally effective and tolerated in children and adolescents. These findings suggest that pharmacological differences in tolerability or ADHD symptom response are negligible between children and adolescents.

AB - Objective: Controversy exists over changes in tolerability and response to medications across the life span. Here the authors report data contrasting the efficacy and tolerability of atomoxetine between children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Method: Data were analyzed for children ages 6-11 (510 atomoxetine, 341 placebo) and adolescents ages 12-17 (107 atomoxetine, 69 placebo) with DSM-IV-defined ADHD enrolled in similarly designed, double-blind, placebo-controlled trials. Efficacy measures included response rates, times to response, and mean changes from baseline to endpoint in the ADHD Rating Scale, Conners' Parent Rating Scale, and Clinical Global Impressions. Results: Adolescents had lower baseline ADHD scores compared with children. There were no statistically significant differences in the overall effects on ADHD symptoms, response rates, or time to response between age groups. Children, but not adolescents, had higher rates of somnolence and headache relative to placebo. No other clinically meaningful treatment differences were seen in adverse event rates, vital signs, weight, height, laboratory values, or ECG between children and adolescents. Conclusions: Acute atomoxetine treatment appears to be equally effective and tolerated in children and adolescents. These findings suggest that pharmacological differences in tolerability or ADHD symptom response are negligible between children and adolescents.

KW - Adolescents

KW - Age

KW - Atomoxetine

KW - Attention-deficit/hyperactivity disorder

KW - Children

UR - http://www.scopus.com/inward/record.url?scp=31444442249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444442249&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000190352.90946.0b

DO - 10.1097/01.chi.0000190352.90946.0b

M3 - Article

VL - 45

SP - 149

EP - 157

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 2

ER -